Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan pediatric formulation trial in neonates with persistent pulmonary hypertension of the newborn
NL-OMON20918Not yet recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in persistent pulmonary hypertension of the newborn (PPHN) comparing Bosentan plus standard supportive care with Placebo plus standard supportive care (2 arms). Primary endpoint: Primary efficacy, pharmacokinetics, tolerability, and safety assessment. Planned start Sep 2011; status: not yet recruiting.
02
Drugs
bosentan
03
Conditions
persistent pulmonary hypertension of the newborn (PPHN)
Beyond the preview
Go deeper on NL-OMON20918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20918.